All Stories

  1. Neutralising and Non-neutralising Antibodies to SARS-CoV-2: Role during Infection and in the Evolution of Antigenic structure
  2. Immunotherapeutic Potential of the Yellow Fever Virus Vaccine Strain 17D for Intratumoral Therapy in a Murine Model of Pancreatic Cancer
  3. Neutralizing Antibody Spectrum in COVID-19 Patients who Became Ill During the Circulation of Different SARS-CoV-2 Variants
  4. Experimental Use of Common Marmosets (<i>Callithrix jacchus</i>) in Preclinical Trials of Antiviral Vaccines
  5. A Chimeric Vaccine Based on a Single Fusion Protein (W-PreS-O) Combining RBDs from Wuhan hu-1 Wild Type and Omicron Shows Protective Effect against Omicron Infection in Syrian Hamsters
  6. Swelling, Rupture and Endosomal Escape of Biological Nanoparticles Per Se and Those Fused with Liposomes in Acidic Environment
  7. Swelling, Rupture and Endosomal Escape of Biological Nanoparticles per se and Those Fused with Liposomes in Acidic Environment
  8. Correction: Zhitkevich et al. HIV-1 Reverse Transcriptase Expression in HPV16-Infected Epidermoid Carcinoma Cells Alters E6 Expression and Cellular Metabolism, and Induces a Hybrid Epithelial/Mesenchymal Cell Phenotype. Viruses 2024, 16, 193
  9. HIV-1 Reverse Transcriptase Expression in HPV16-Infected Epidermoid Carcinoma Cells Alters E6 Expression and Cellular Metabolism, and Induces a Hybrid Epithelial/Mesenchymal Cell Phenotype
  10. Expressed in HPV 16 Infected Epidermoid Carcinoma Cells, HIV‐1 Reverse Transcriptase Shifts Their Metabolism towards aerobic Glycolysis, Induces Hybrid E/M Cell Phenotype and Increases Expression of E6 Transcripts
  11. Safety and Immunogenicity of Inactivated Whole Virion COVID-19 Vaccine CoviVac in Clinical Trials in 18–60 and 60+ Age Cohorts
  12. Common Marmoset Cell Lines and Their Applications in Biomedical Research
  13. The informative value of noninvasive tools for assessment of liver fibrosis in chronic hepatitis B patients under antiviral treatment with nucleoside and nucleotide analogues
  14. Predictors of treatment efficacy with nucleos(t)ide analogues for chronic hepatitis B
  15. Transient and tunable CRISPRa regulation of APOBEC/AID genes for targeting hepatitis B virus
  16. Clinical and virological characteristics of chronic hepatitis b and response to antiviral therapy
  17. Depleting hepatitis B virus relaxed circular DNA is necessary for resolution of infection by CRISPR-Cas9
  18. Hydroxychloroquine Enhances Cytotoxic Properties of Extracellular Vesicles and Extracellular Vesicle–Mimetic Nanovesicles Loaded with Chemotherapeutics
  19. HIV-1 Protease as DNA Immunogen against Drug Resistance in HIV-1 Infection: DNA Immunization with Drug Resistant HIV-1 Protease Protects Mice from Challenge with Protease-Expressing Cells
  20. Geographic and Temporal Variability of Hepatitis E Virus Circulation in the Russian Federation
  21. Hydroxychloroquine Enhances Cytotoxic Properties of Extracellular Vesicles and Extracellular Vesicle-Mimetic Nanovesicles Loaded with Chemotherapeutics
  22. Geographic and Temporal Variability of Hepatitis E Virus Circulation in Non-Endemic Territories
  23. Immunogenicity and protectivity of intranasally delivered vector-based heterologous prime-boost COVID-19 vaccine Sputnik V in mice and non-human primates
  24. Vaccination With Oral Polio Vaccine Reduces COVID-19 Incidence
  25. Hepatitis B, C and TTV virus infection in highly trained athletes
  26. Immunization with recombinant ORF2 p551 protein protects common marmosets (Callithrix jacchus) against homologous and heterologous hepatitis E virus challenge
  27. Immunity and Viral Infections: Modulating Antiviral Response via CRISPR–Cas Systems
  28. Cellular Immune Response Induced by DNA Immunization of Mice with Drug Resistant Integrases of HIV-1 Clade A Offers Partial Protection against Growth and Metastatic Activity of Integrase-Expressing Adenocarcinoma Cells
  29. Reciprocal Inhibition of Immunogenic Performance in Mice of Two Potent DNA Immunogens Targeting HCV-Related Liver Cancer
  30. Correction: DNA immunization site determines the level of gene expression and the magnitude, but not the type of the induced immune response
  31. Corrigendum to isolation and phylogenetic analysis of SARS-CoV-2 variants collected in Russia during the COVID-19 outbreak [Int. J. Infect. Dis. 99 (2020) 40-46]
  32. Long-term humoral immunogenicity, safety and protective efficacy of inactivated vaccine against COVID-19 (CoviVac) in preclinical studies
  33. Preclinical studies of immunogenity, protectivity, and safety of the combined vector vaccine for prevention of the middle east respiratory syndrome
  34. Isolation and phylogenetic analysis of SARS-CoV-2 variants collected in Russia during the COVID-19 outbreak
  35. Expression of the Reverse Transcriptase Domain of Telomerase Reverse Transcriptase Induces Lytic Cellular Response in DNA-Immunized Mice and Limits Tumorigenic and Metastatic Potential of Murine Adenocarcinoma 4T1 Cells
  36. A heterologous virus-vectored vaccine for prevention of Middle East respiratory syndrome induces long protective immune response against MERS-CoV
  37. HIV-1 Reverse Transcriptase Promotes Tumor Growth and Metastasis Formation via ROS-Dependent Upregulation of Twist
  38. Replenishment of Hepatitis B Virus cccDNA Pool Is Restricted by Baseline Expression of Host Restriction Factors In Vitro
  39. ATM and ATR Expression Potentiates HBV Replication and Contributes to Reactivation of HBV Infection upon DNA Damage
  40. The First Complete Genome Sequences of Hepatitis C Virus Subtype 2b from Latin America: Molecular Characterization and Phylogeographic Analysis
  41. Therapeutic Vaccines Against Human Papilloma Viruses: Achievements and Prospects
  42. Assessment of the Parameters of Adaptive Cell-Mediated Immunity in Naïve Common Marmosets (Callithrix jacchus)
  43. DNA immunization site determines the level of gene expression and the magnitude, but not the type of the induced immune response
  44. Immunization of Domestic Ducks with Live Nonpathogenic H5N3 Influenza Virus Prevents Shedding and Transmission of Highly Pathogenic H5N1 Virus to Chickens
  45. The Evaluation of Pharmacodynamics and Pharmacokinetics of Anti-thrombin DNA Aptamer RA-36
  46. Impact of Universal Hepatitis B Vaccination on Prevalence, Infection-Associated Morbidity and Mortality, and Circulation of Immune Escape Variants in Russia
  47. Immunization with live nonpathogenic H5N3 duck influenza virus protects chickens against highly pathogenic H5N1 virus
  48. P192: Hepatitis E epidemic process in Russian Federation
  49. P202: Rabbit hepatitis E virus circulation in endemic and non-endemic regions